Analyst Thinks This Pharma Stock Could Lose 60%

The analyst started BOLD stock with an underperform rating

Digital Content Manager
Oct 3, 2019 at 11:32 AM
facebook twitter linkedin


Drugmaker Audentes Therapeutics Inc (NASDAQ:BOLD) is down 1.4% at $27.32 today, after Baird initiated coverage on the stock with an "underperform" rating. The analyst also slapped BOLD with a $10 price target, which is roughly a 64% discount to last night's close of $27.69, and would represent a new record low for the stock. 

Generally, analysts have been quite bullish on the pharma name. Prior to today, nine in coverage called BOLD a "buy" or better, while only two said "hold" or worse. What's more, the stock's consensus 12-month price target of $43 sits near its June 2018 all-time peak, and holds a 57.7% premium to current levels. 

While the security is still up 28.7% for the year, it has lost about 31% since running out of steam at the $40.50 region in late July. The 40-day moving average contained BOLD's last attempt at a rally. Now, it's testing support at the $26 area -- near where the equity was trading prior to a February bull gap.

BOLD Oct 3

In the options pits, traders have tended toward bearish bets, with 4.13 long puts bought for every call in the past 10 weeks. This is echoed in the equity's Schaeffer's put/call open interest ratio (SOIR) of 1.06, which sits in the 90th percentile of its annual range, suggesting short-term options players have rarely been more put-heavy during the past 12 months. 

Short sellers have been upping the bearish ante too, with short interest rising 5.4% in the last two reporting periods, to 2.03 million shares sold short. This represents a healthy 7.3% of the stock's available float, and nearly a week's worth of buying demand, at its average pace of trading. 

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners